English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Pharmaceutical giant Merck will acquire its rival Schering-Plough in a US$41billion deal announced on 9 March and unanimously approved by the boards of the New Jersey-based companies. The move is seen as a way to protect the company’s drug-development pipeline. The new company, which will be called Merck, would have 18 drugs in phase-III development, double what Merck had before. It also opens new markets for Merck: Schering-Plough earns 70% of its annual revenue outside the United States, including more than $2 billion from emerging markets. The deal is the latest in a series of drug-industry marriages: Pfizer paid $68 billion in January to acquire Wyeth, and Roche recently boosted its offer to buy out Genentech to $46 billion.

Mars orbiter plans to map out methane plumes